Evidence map›Paper›PMID 24718889›Full record

SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2014

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

Y Y Juo, F M Johnston, D Y Zhang, H H Juo, H Wang, E P Pappou, T Yu, H Easwaran, S Baylin, M van Engeland and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Y Y JuoDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore.
F M JohnstonDepartment of Surgery, Medical College of Wisconsin, Milwaukee.
D Y ZhangDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore.
H H JuoDepartment of Internal Medicine, Danbury Hospital, Danbury.
H WangDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore.
E P PappouDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore.
T YuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore.
H EaswaranDepartment of Oncology.
S BaylinDepartment of Oncology; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA; Department of Sidney Kimmel Cancer Center, Baltimore USA.
M van EngelandDepartment of pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
N AhujaDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore; Department of Oncology; Department of Sidney Kimmel Cancer Center, Baltimore USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, USA. Electronic address: nahuja@jhmi.edu.

Funding

Epigenetic markers involved in colorectal cancer recurrence and metastasesK23CA127141 · NCI · JOHNS HOPKINS UNIVERSITY · PI AHUJA, NITA · 2008 to 2012
$705k
NCI NIH HHS K23 CA127141
6 · The paper itself

Abstract

backgroundDivergent findings regarding the prognostic value of CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) patients exist in current literature. We aim to review data from published studies in order to examine the association between CIMP and CRC prognosis. MATERIALS AND

methodsA comprehensive search for studies reporting disease-free survival (DFS), overall survival (OS), or cancer-specific mortality of CRC patients stratified by CIMP is carried out. Study findings are summarized descriptively and quantitatively, using adjusted hazard ratios (HRs) as summary statistics.

resultsThirty-three studies reporting survival in 10 635 patients are included for review. Nineteen studies provide data suitable for meta-analysis. The definition of CIMP regarding gene panel, marker threshold, and laboratory method varies across studies. Pooled analysis shows that CIMP is significantly associated with shorter DFS (pooled HR estimate 1.45; 95% confidence interval (CI) 1.07-1.97, Q = 3.95, I(2) = 0%) and OS (pooled HR estimate 1.43; 95% CI 1.18-1.73, Q = 4.03, I(2) = 0%) among CRC patients irrespective of microsatellite instability (MSI) status. Subgroup analysis of microsatellite stable (MSS) CRC patients also shows significant association between shorter OS (pooled HR estimate 1.37; 95% CI 1.12-1.68, Q = 4.45, I(2) = 33%) and CIMP. Seven studies have explored CIMP's value as a predictive factor on stage II and III CRC patient's DFS after receiving adjuvant 5-fluorouracil (5-FU) therapy: of these, four studies showed that adjuvant chemotherapy conferred a DFS benefit among CIMP(+) patients, one concluded to the contrary, and two found no significant correlation. Insufficient data was present for statistical synthesis of CIMP's predictive value among CRC patients receiving adjuvant 5-FU therapy.

conclusionCIMP is independently associated with significantly worse prognosis in CRC patients. However, CIMP's value as a predictive factor in assessing whether adjuvant 5-FU therapy will confer additional survival benefit to CRC patients remained to be determined through future prospective randomized studies.

Indexed as

CpG IslandsDNA MethylationColorectal NeoplasmsHumansPhenotypePrognosisadjuvant chemotherapyCIMPcolorectal cancerepigeneticsprognosistumor marker

Identifiers

PMID24718889
PMCPMC4239805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.